Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
396actual
Sites
17
Countries
Spain, United Kingdom, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-10-11 | actual | When the study began enrolling |
| Primary completion | 2024-09-16 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-06-24 | estimated | The whole study's end, after follow-up |
| First posted | 2018-08-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- ER+ HER2- Advanced Breast Cancer
Interventions
- Drug: AZD9833
- Drug: AZD9833
- Drug: AZD9833 with palbociclib
- Drug: AZD9833 with palbociclib
- Drug: AZD9833 with everolimus
- Drug: AZD9833 with everolimus
- Drug: AZD9833 with abemaciclib
- Drug: AZD9833 with abemaciclib
- Drug: AZD9833 with capivasertib
- Drug: AZD9833 with capivasertib
- Drug: AZD9833 with ribociclib
- Drug: AZD9833 with ribociclib
- Drug: AZD9833 with anastrozole
- Drug: AZD9833 with anastrozole
Primary outcomes
what the primary-completion date above is the date OFThe number of subjects with dose-limiting toxicity, as defined in the protocol.
measured Minimum observation period 28 days on treatment.
The number of subjects with treatment-related adverse events as assessed by CTCAE v4.03.
measured Minimum observation period 28 days on treatment, and will continue until the subject is off the study (approximately 1 year).
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed